1st May 2018 13:31
LONDON (Alliance News) - SkinBioTherapeutics PLC on Tuesday said it has finished designing a human study planned for its SkinBiotix proposed treatment.
The study is scheduled to begin in the third quarter of 2018 and will be conduced by clinical research firm Alba Science Ltd in Edinburgh. The six week study will look at 120 participants with 'dry skin'.
It will measure, SkinBio said, visual assessments of skin dryness, skin hydration, and skin barrier function.
SkinBiotix will be applied as a cream three times daily, and the company said the entire study should take around eight weeks.
The product has also been granted a patent in New Zealand and Russia, it said, and it is looking to get this done in more key markets such as Europe, the US, and China.
SkinBio also said Tuesday it has successfully trialled a new manufacturing process for lysate, with the new process having no detrimental impact on the SkinBiotix technology.
Chief Executive Cath O'Neill said: "We are really pleased with the progress we have made across design of the human efficacy study and with the upscaling of the lysate manufacturing.
"We are determined to make the study as impactful as possible, which is why we have doubled its size. The cost impact is marginal, but the increase in the strength of the potential data and hence, to future partnering discussions, could be significant. Scaling up the manufacturing process is a key step in our development, and we are also moving this forward very well."
Shares were up 5.8% on Tuesday at 14.15 pence each.
Related Shares:
Skinbiotherap.